Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743522 · ClinicalTrials.gov registry record
Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
A clinical trial of Shock, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 1,670
- Enrollment target
- 1
- Study location
NCT00743522 is a study of Shock that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,670 participants, above the 296-participant average among 9 other Shock trials with a reported enrollment target (464% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00743522, a study of Shock, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 1,670 participants
- Enrollment target
- 1
- Study location
Study Summary
Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number of shocks in primary prevention patients. In addition to shock therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE trial aims to prospectively study the effect of high detection rates, prolonged detection intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to first shock in primary prevention patients.
Conditions Studied
Interventions
- DEVICE ICD/ CRT-D
Study Locations (1)
Texas
- Hall-Garcia Cardiology Associates - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,670 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743522
The ClinicalTrials.gov registry entry for NCT00743522 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,670 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 296-participant average among 9 other Shock trials with a reported enrollment target (464% higher). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Shock appearing as the primary indexed condition, and to 1 intervention - of which ICD/ CRT-D is the first listed.
NCT00743522 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00743522 about?
NCT00743522 is a clinical study titled "Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication". Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number ...
What is the current status of trial NCT00743522?
This trial is currently completed. The enrollment target is 1,670 participants. The study started on 2008-09. Estimated completion is 2011-12.
What conditions does trial NCT00743522 study?
This clinical trial studies the following conditions: Shock.
What interventions are being tested in trial NCT00743522?
The interventions under investigation include: ICD/ CRT-D (DEVICE).
Who is sponsoring clinical trial NCT00743522?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00743522 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
-
Resuscitative TEE Collaborative Registry
RECRUITING
-
Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning
RECRUITING · NA
-
Central Line Study
RECRUITING · Phase 4
-
Vasoactive Drugs in Intensive Care Unit
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.